Tonix's Tonmya Disappoints in Second Phase III PTSD Study
But Fibromyalgia Study Continues
Executive Summary
Tonix Pharmaceuticals’ sublingual cyclobenzaprine has failed to show better efficacy than placebo in an interim analysis of the Phase III RECOVERY trial in post-traumatic stress disorder patients, although the study will continue to completion in already-enrolled patients. The product is also in development for fibromyalgia.
You may also be interested in...
Tonix Shutters MDD Candidate After Phase II Miss
Tonix’s once-daily formulation of tianeptine, widely used to treat depression in Europe, failed to improve depression severity in a Phase II study and will be discontinued, the latest R&D setback for the biotech.
Bionomics Posts Positive Data In PTSD With Struggling Anxiety Drug
After failing in a Phase II trial in social anxiety disorder, Bionomics thinks mid-stage data for BNC210 in post-traumatic stress disorder may now position the drug as a novel therapy for PTSD.
Keeping Track: Good News For Deciphera, BMS And Clovis; Bad News For bluebird/BMS, Blueprint And Tonix
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.